Email bulletins

Archive

September 2018

  • DAA treatment highly effective for people who use drugs
  • HCV elimination in people who inject drugs
  • Little progress towards universal testing of 'baby boomer' generation in United States
  • Reinfection risk higher in recent drug users
  • Screening pregnant women and infants for hepatitis C
  • Psychological relief is the most important benefit of being cured of hepatitis C, say patients
  • Safety and effectiveness of DAAs in older people
  • Is this your copy of the infohep news bulletin?

August 2018

  • End-stage liver disease deaths due to hepatitis C fall in the United Kingdom and Australia
  • Supervised drug consumption rooms and hepatitis C testing and treatment
  • Injecting drug users in South Africa: a high prevalence of HCV
  • Transplants using organs from donors with HCV
  • China Gilead patent
  • Zepatier price cut
  • Is this your copy of the infohep news bulletin?

July 2018

  • World Hepatitis Day
  • Treat all with hepatitis C, World Health Organization recommends
  • Identifying people in need of hepatitis B treatment in Africa
  • Hepatitis C treatment for people without liver damage
  • Improved survival after liver transplant
  • Access to HCV treatment for people with substance use or mental health issues
  • Ramucirumab for liver cancer
  • Is this your copy of the infohep news bulletin?

June 2018

  • Hepatitis C testing and treatment in prisons
  • Scotland and harm reduction
  • Hepatitis C treatment and payer coverage in US
  • Birth cohort testing in Canada
  • Hepatitis C testing in community pharmacies
  • Hepatitis C drugs to be discontinued
  • Treatment for NASH
  • 7th International Symposium on Hepatitis Care in Substance Users
  • 2nd HEP-C Community Summit
  • Is this your copy of the infohep news bulletin?

May 2018

  • Quality of life after hepatitis C cure
  • Portal hypertension after hepatitis C cure
  • Cardiovascular disease risk and sustained virologic response
  • Myrcludex: treatment for hepatitis delta
  • Tenofovir alafenamide as treatment for hepatitis B
  • Experimental treatment for hepatitis B
  • Hepatitis C elimination in Georgia
  • Treatment for hepatitis C in Africa
  • Is this your copy of the infohep news bulletin?

April 2018

  • News from the 2018 International Liver Congress, Paris
  • Effectiveness of hepatitis C treatment
  • EASL HCV treatment guidelines
  • Liver cancer treatment guidelines
  • Liver cancer treatment
  • Liver cancer risk after DAA treatment
  • Access to treatment
  • Cost-effectiveness of early treatment for hepatitis C
  • Shorter treatment courses for genotype 3
  • Is this your copy of the infohep news bulletin?

March 2018

  • WHO progress report on access to treatment
  • Hepatitis B: five countries account for more than half of all HBV infections
  • Prevention of mother-to-child transmission of hepatitis B
  • Hepatitis C elimination in prisoners
  • Eliminating hepatitis C in England
  • Successful HCV therapy reduces the risk of diabetes
  • Next month: News from The International Liver Congress
  • Is this your copy of the infohep news bulletin?

February 2018

  • Harm reduction scale-up needed to reduce HCV prevalence among people who inject drugs
  • Slowdown in new treatment uptake for hepatitis C starts in Australia
  • Hepatitis C elimination in Georgia
  • Improvement in fibrosis after hepatitis C cure
  • Smoking in people with hepatitis C
  • Is this your copy of the infohep news bulletin?

January 2018

  • NHS England aims for hepatitis C elimination by 2025
  • Hepatitis B and secondary liver cancer
  • Smoking and survival after liver cancer diagnosis
  • Real world data on treatment success in people with HIV/HCV co-infection
  • Is this your copy of the infohep news bulletin?
201820172016201520142013